Carmot Therapeutics Inc. has divulged benzimidazoyl compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of metabolic diseases.
Taisho Pharmaceutical Co. Ltd. has synthesized sulfonamide-containing peptides acting as MMP-7 (matrilysin) inhibitors reported to be useful for the treatment of cancer.
Scientists at the University of Turin and the University of Pisa have identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, neurodegeneration, cancer, cardiovascular disorders, and autoimmune and metabolic disease.
Benevolentai Bio Ltd. has discovered imidazopyridazine derivatives acting as high-affinity nerve growth factor receptor (NTRK1) and/or BDNF/NT-3 growth factor receptor (NTRK2) and/or NT-3 growth factor receptor (NTRK3) inhibitors reported to be useful for the treatment of atopic dermatitis.
Voronoi Inc. has identified heteroaryl compounds acting as HER2 (erbB2) and/or HER4 (erbB4) inhibitors reported to be useful for the treatment of cancer.
Nuvation Bio Inc. has disclosed drug conjugates comprising a nuclear receptor-targeting moiety covalently linked to a poly(ADP-ribose) polymerase 1 (PARP1) and/or PARP2 inhibitor though a linker. They are reported to be potentially useful for the treatment of cancer.
Merck KGaA and Cancer Research Technology Ltd. have synthesized 2,8-dihydropyrazolo[3,4-b]indoles acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, cardiovascular disorders and liver fibrosis.
RSS
